NCT04766723 - A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

November 20, 2023

Conditions

Essential Tremor of the Upper Limb

Interventions

DRUG

NT 201

Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

DRUG

Placebo

Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Trial Locations (14)

10029

Mount Sinai Medical Center, Merz Investigational Site #0010191, New York

22101

Medstar Georgetown Neurology, Merz Investigational Site #0010231, McLean

33612

USF, Department of Neurology, Merz Investigational Site #0010020, Tampa

37232

Vanderbilt University Medical Center, Neuroscience Institute, Merz Investigational Site #0010206, Nashville

68131

University of Nebraska Medical Center, Merz Investigational Site #0010269, Omaha

77030

Houston Methodist Neurological Institute, Merz Investigational Site #0010226, Houston

89106

Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457, Las Vegas

98195

UW Medical Center - Montlake, Merz Investigational Site #0010450, Seattle

99202

Selkirk Neurology, Merz Investigational Site #0010456, Spokane

N6A 5A5

London Health Sciences Centre, Merz Investigational Site #0010087, London

30-539

Specjalistyczne Gabinety, Merz Investigational Site #0480059, Krakow

90-640

NeuroKlinika Gabinet Lekarski, Merz Investigational Site #0480101, Lodz

32-600

Instytut Zdrowia Dr. Boczarska-Jedynak, Oświęcim

03-242

Mazowiecki Szpital Bródnowski, Merz Investigational Site #0480064, Warsaw